Mitoxantrone in MS: AAN report


The AAN Therapeutics and Technology Assessment subcommittee has published its report on the safety and efficacy of mitoxantrone in multiple sclerosis, concluding that the risks of systolic dysfunction and therapy-related leukemia are higher than previously estimated (Marriott et al. Neurology 2010; 74: 1463-1470; free full text at

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page